Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the full market launch of Opus™ BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005140/en/
Available in putty and strip formulations, Opus BA can be used to fill bone voids or gaps in the skeletal system that are not intrinsic to the stability of bony structure. Opus BA acts as a scaffold allowing bone growth across the surface that is reabsorbed and replaced with natural bone during the healing process. Easily hydrated with autogenous bone marrow or autograft with saline, Opus BA is moldable and ideal for versatile applications.
Orthofix recognizes the important role of a comprehensive offering of biologic solutions in spine and orthopedic surgical applications. The Company proudly markets and distributes the Trinity Elite™ and Trinity Evolution™ allografts with viable cells, FiberFuse™ Advanced moldable allograft, FiberFuse Strip™ preformed allograft, AlloQuent™ structural allograft, VersaShield™ amniotic membrane, Opus™ Mg Set bone void filler, Collage™ osteoconductive scaffold, and the O-Genesis™ graft delivery system. This broad portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.
